Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DexCom
DXCM
5
Workday
WDAY
US Stock MarketDetailed Quotes
CYCC Cyclacel Pharmaceuticals
- 0.2785
- +0.0495+21.62%
Close Apr 25 16:00 ET
- 0.2901
- +0.0116+4.17%
Pre 05:28 ET
57.74MMarket Cap-0.13P/E (TTM)
0.3000High0.2263Low3.75MVolume0.2340Open0.2290Pre Close975.95KTurnover29.48%Turnover RatioLossP/E (Static)207.34MShares3.083552wk High-27.85P/B3.54MFloat Cap0.170652wk Low--Dividend TTM12.71MShs Float2141994.0840Historical High--Div YieldTTM32.18%Amplitude0.1706Historical Low0.2600Avg Price1Lot Size
About Cyclacel Pharmaceuticals Company
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on January 5, 1996 and is headquartered in Berkeley Heights, NJ.
Company Profile
SymbolCYCC
Company NameCyclacel Pharmaceuticals
Listing DateMar 16, 2004
Issue Price8.00
Founded1996
CEOMs. Sing Ee Doris Wong
MarketNASDAQ
Employees12
Fiscal Year Ends12-31
Address200 Connell Drive,Suite 1500
CityBerkeley Heights
ProvinceNew Jersey
CountryUnited States of America
Zip Code07922
Phone1-908-517-7330
Websitehttp://www.cyclacel.com
Company Executives
- Name
- Position
- Salary
- Dr. Doris Wong Sing Ee
- Director and Chief Executive Officer
- --
- Dr. Doris Wong Sing Ee
- Chief Executive Officer and Chairman of the Board
- --
- Kiu Cu Seng
- Director, Co-Principal Financial Officer, Co-Principal Accounting Officer and Secretary
- --
- Kwang Fock Chong
- Independent Director
- --
- Inigo Angel Laurduraj
- Independent Director
- --
- Dr. Satis Waran Nair Krishnan
- Independent Director
- --
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now